Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TNK1 | Q13470 | 3/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2366988 | 0.99 | PARP1 (0.80) | PARP1KCNH2PARP2KDM4EALDH1A1 | |
| SCHEMBL2385716 | 0.99 | PARP1 (0.84) | PARP1KCNH2PARP2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2380617 | 0.98 | PARP1 (0.82) | PARP1KCNH2PARP2KDM4EALDH1A1 | |
| SCHEMBL2367022 | 0.90 | PARP1 (1.00) | PARP1KCNH2PARP2TNK1TNK2 | |
| Hydrochloric Acid SCHEMBL2366261 | 0.89 | PARP1 (0.98) | PARP1KCNH2PARP2TNK1TNK2 | |
| SCHEMBL2366943 | 0.83 | PARP1 (1.00) | PARP1 | |
| Hydrochloric Acid SCHEMBL2366803 | 0.82 | PARP1 (0.98) | PARP1 | |
| Hydrochloric Acid SCHEMBL2366657 | 0.82 | PARP1 (0.98) | PARP1 | |
| SCHEMBL23220875 | 0.81 | PARP1 (0.64) | PARP1KCNH2PARP2TNK1TNK2 | |
| SCHEMBL2367027 | 0.81 | PARP1 (1.00) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | claimed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | claimed |
| EP-2364983-A2 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2011-09-14 | — | — | EP | claimed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | claimed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815891-B2 | Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2364983-B1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2364983-A2 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2011-09-14 | — | — | EP | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218193-A1 | NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PARP1, PARP15, PARP11 | PARP1 1/4885KCNH2 3365/4885PARP2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.